Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab in HIV undergoing ATI
NCT02788175Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2016
- Primary completion
- Mar 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vedolizumab in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Number of Grade 2 or Higher Related Adverse Events at 72 weeks. Started May 2016; status: completed.
02
Drugs
vedolizumab
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02788175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02788175.